Welcome, everyone, to the JPMorgan Healthcare Conference. We are pleased to have with us the Almirall management team here with us today, Carlos Gallardo, Chairman and CEO; Karl Ziegelbauer, CFO; Jon ...

A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

Investigators evaluated the efficacy and safety of toripalimab versus dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.

For children with established AD and food allergies, early systemic therapy, including dupilumab and JAK inhibitors, may interrupt progression along the atopic march, with data supporting both ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Oral anticoagulant use was associated with a reduced risk for progression of 60% and a reduced risk for death of 76% in ...

A personalised mRNA vaccine developed by Moderna and Merck shows lasting benefits for patients with high-risk skin cancer.

Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in patients with high-risk resected melanoma over 5 years. The personalized mRNA therapy targets ...

The Central Drugs Standard Control Organisation (CDSCO) has granted multiple CT-18 approvals between January 2020 and ...